C4 Therapeutics (CCCC) Corporate presentation summary

Strategic vision and financial outlook

• Advancing a high-value clinical oncology portfolio with a focus on multiple myeloma (MM) and non-small cell lung cancer (NSCLC).

• Discovery strategy now targets inflammation, neuroinflammation, and neurodegeneration (INN) for pipeline sustainability.

• Cash runway projected through end of 2028, supporting execution beyond key value inflection points.

• Vision to become a fully integrated biopharmaceutical company with best- and first-in-class degraders.

Clinical pipeline and development milestones

• Cemsidomide, a next-generation IKZF1/3 degrader, is in Phase 2 (MOMENTUM) and Phase 1b trials for MM, including combinations with elranatamab.

• CFT8919, an EGFR L858R degrader, is advancing for NSCLC, with ex-China development informed by ongoing trials.

• Three potential INDs from the INN discovery pipeline targeted by year-end 2028.

• Multiple strategic milestones expected, including NDA submission for cemsidomide by end of 2028.

Cemsidomide clinical and market potential

• Phase 1 data show cemsidomide has a wide therapeutic index, strong anti-myeloma activity, and a differentiated safety profile.

• Positioned for accelerated approval in both 2L+ and 4L+ MM, with efficient regulatory paths.

• Estimated peak revenue opportunity of $2.5–$4B for initial cemsidomide indications.

• Large and growing 4L+ MM patient population with high unmet need; cemsidomide addresses this gap.